XOMA (NASDAQ:XOMA) Raised to “Hold” at StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $123.00 target price on shares of XOMA in a research note on Tuesday, January 7th.

XOMA Price Performance

NASDAQ:XOMA opened at $28.12 on Thursday. XOMA has a one year low of $18.57 and a one year high of $35.00. The stock has a market cap of $331.34 million, a PE ratio of -8.08 and a beta of 0.92. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock has a 50 day moving average price of $28.81 and a 200 day moving average price of $28.02.

Insider Activity

In other news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of XOMA. Bank of New York Mellon Corp raised its stake in shares of XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after acquiring an additional 1,968 shares during the period. Rhumbline Advisers raised its position in XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. Ellsworth Advisors LLC purchased a new stake in XOMA in the third quarter valued at approximately $516,000. BNP Paribas Financial Markets boosted its holdings in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the period. Finally, State Street Corp grew its position in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.